Novo Nordisk, Denmark's biggest pharmaceutical company, has established a new unit with the ambition of making RNA and gene therapy available across all of its therapy areas, Senior Vice President of Global Research Technologies at Novo Nordisk tells Medwatch.
"One of the main reasons we are taking this leap is our belief that RNA and gene therapy could be used within all of Novo Nordisk's therapy areas," Fogh Iversen says.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.